FDA Approves ENHERTU — Daiichi Sankyo Inc.

# FDA Approves Daiichi Sankyo's ENHERTU for HER2-Positive Cancers The FDA has approved Daiichi Sankyo Inc.'s ENHERTU (fam-trastuzumab deruxtecan-nxki), an intravenous HER2-targeted antibody-drug conjugate, positioning the Japanese pharmaceutical company to compete in the lucrative oncology market dominated by Roche's Herceptin. The approval establishes ENHERTU as a potential blockbuster therapy for HER2-positive breast cancer and